Health Boards
Wed-12-12-2018, 18:54 PM
(This post was last modified: Wed-12-12-2018, 18:57 PM by Caroline. Edited 1 time in total.)
It is obvious, could even be easily predicted, there is no science necessary for that.
IL-23 is an interleukin associated most with Psoriasis
IL-17 is an interleukin associated mostly with Psoriactic Arthritis.
What would be the outcome of you compare them for Psoriasis?
now that cannot be difficult to answer.
If you would compare them for Psoriactic Arthritis, then the header would read: “Consentyx beats Tremfya on Psoriactic Arthritis”
There is no need for scientific research on this one, this is only commercial and window dressing of Janssen’s
And Tremfya is not the first IL-23 inhibitor, that would be Stelara.
IL-23 is an interleukin associated most with Psoriasis
IL-17 is an interleukin associated mostly with Psoriactic Arthritis.
What would be the outcome of you compare them for Psoriasis?
now that cannot be difficult to answer. If you would compare them for Psoriactic Arthritis, then the header would read: “Consentyx beats Tremfya on Psoriactic Arthritis”
There is no need for scientific research on this one, this is only commercial and window dressing of Janssen’s
And Tremfya is not the first IL-23 inhibitor, that would be Stelara.
